News

CLINUVEL
Posted by CLINUVEL
May 25, 2022

Notice of change of interests of initial substantial holder

Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 20, 2022

Notice of initial substantial holder

Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 13, 2022

Strategic Update IV

CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...

Read More
CLINUVEL
Posted by CLINUVEL
May 12, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo treatment program

A new potential therapy for the pigment loss disorder vitiligo will undergo...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo study

CLINUVEL today announced that it will start treatment of vitiligo patients with...

Read More
CLINUVEL
Posted by CLINUVEL
May 6, 2022

Notification regarding unquoted securities

Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 4, 2022

Positive final results in stroke

CLINUVEL today released positive final results of the open label pilot study...

Read More
CLINUVEL
Posted by CLINUVEL
April 29, 2022

CEO letter

For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...

Read More
CLINUVEL
Posted by CLINUVEL
April 28, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More